As a result of the constantly increasing number of innovative but exceedingly high priced medicines, many Member States have implemented price-regulating mechanisms to ensure the financial viability of their healthcare systems. However, the European Court of Justice applies strict criteria to these measures - some of them have already been suspended for the purposes of the free movement of goods. The European Union (EU) allowed the development of an ever-stricter case law on one hand, without changing the legal frame on the other hand. Considering the importance and the binding nature of the Court's judgements, this leaves great uncertainty for national legislators about which measures to remedy the pricing problem are legally possible and which are not. In order to provide clarity, this article seeks to analyse the development of the case law and to define the legal scope for pharmaceutical pricing mechanisms in the EU.

中文翻译：

---

什么是可能的，什么不是？欧盟药品定价机制法律框架的发展

由于不断创新但价格过高的药品数量不断增加，许多会员国实施了价格调节机制以确保其医疗保健系统的财务可行性。但是，欧洲法院对这些措施采用严格的标准-其中某些措施已经出于货物自由流通的目的而被暂停。欧盟（EU）一方面允许制定越来越严格的判例法，另一方面又不改变法律框架。考虑到法院判决的重要性和具有约束力的性质，这给国家立法者带来了很大的不确定性，即哪些法律措施可以合法地解决价格问题，哪些法律途径不可行。为了清楚起见，